Ph+ CML Monitoring
How is Ph+ CML monitored?
Your healthcare provider may perform tests of your blood and bone marrow Bone marrow: the soft tissue inside bones that produces blood cells at various time points after starting treatment. These tests may be scheduled at 3 months, 6 months, 12 months, and beyond. Your testing schedule (how often you will have tests performed in the future) will be determined by your healthcare provider.
What Tests Are Used To Evaluate and Monitor Ph+ CML?
*The approval of SPRYCEL for Ph+ CML patients who are no longer benefiting from, or cannot tolerate, current treatment, including imatinib, was not based on results of this kind of testing.
Why Is Ongoing Testing and Monitoring Important?
Ongoing testing and monitoring is very important to help you and your doctor understand if your Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) is being controlled appropriately over the long term. The goal of testing is to determine if your blood counts are improving and the number of leukemia cells is decreasing. These tests can also tell your doctor whether the disease may be resistant to your medicine.
A complete cytogenetic response (CCyR) is an important treatment milestone that means there are no Ph+ cells detected within your blood or bone marrow sample. If you achieve and maintain a CCyR, this means your Ph+ CML is responding to your medicine. It is important to remember that achieving a CCyR does not mean that your Ph+ CML is cured, only that leukemia cells can’t be detected. It is important to continue taking your medication as directed.
If your disease is resistant to SPRYCEL and you are not able to achieve or maintain a CCyR, your doctor may decide to change your treatment.